Icares Medicus Inc (6612) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Icares Medicus Inc (6612) has a cash flow conversion efficiency ratio of -0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-78.58 Million ≈ $-2.48 Million USD) by net assets (NT$1.89 Billion ≈ $59.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Icares Medicus Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Icares Medicus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Icares Medicus Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Icares Medicus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Icares Medicus Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cibus Global LLC
NASDAQ:CBUS
|
-0.615x |
|
Fulin Plastic Industry Cayman Holding Co Ltd
TW:1341
|
0.123x |
|
Grupo Ortiz Properties Socimi
MC:YGOP
|
0.009x |
|
Tillys Inc
NYSE:TLYS
|
0.101x |
|
Frontier Lithium Inc
V:FL
|
0.266x |
|
Cantargia AB
ST:CANTA
|
0.943x |
|
Argent
JSE:ART
|
0.099x |
|
Emerging Display Technologies Corp
TW:3038
|
0.078x |
Annual Cash Flow Conversion Efficiency for Icares Medicus Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Icares Medicus Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Icares Medicus Inc (6612) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.76 Billion ≈ $55.54 Million |
NT$-10.82 Million ≈ $-341.02K |
-0.006x | +60.26% |
| 2023-12-31 | NT$1.67 Billion ≈ $52.58 Million |
NT$-25.79 Million ≈ $-812.43K |
-0.015x | -111.24% |
| 2022-12-31 | NT$937.76 Million ≈ $29.54 Million |
NT$128.92 Million ≈ $4.06 Million |
0.137x | +192.61% |
| 2021-12-31 | NT$820.90 Million ≈ $25.86 Million |
NT$38.57 Million ≈ $1.22 Million |
0.047x | -53.76% |
| 2020-12-31 | NT$702.42 Million ≈ $22.13 Million |
NT$71.37 Million ≈ $2.25 Million |
0.102x | -25.26% |
| 2019-12-31 | NT$653.04 Million ≈ $20.57 Million |
NT$88.78 Million ≈ $2.80 Million |
0.136x | +22.87% |
| 2018-12-31 | NT$571.42 Million ≈ $18.00 Million |
NT$63.22 Million ≈ $1.99 Million |
0.111x | -18.11% |
| 2017-12-31 | NT$336.57 Million ≈ $10.60 Million |
NT$45.47 Million ≈ $1.43 Million |
0.135x | -- |
About Icares Medicus Inc
ICARES Medicus, Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of ophthalmic medical devices in Taiwan, the United States, England, Japan, Spain, China, and internationally. The company is also involved in the manufacturing, sales, and service of intraocular lenses (IOLs) and its implantation systems for use in treating cataracts, myopia, hyper… Read more